Oxford Biomedica PLC
16 December 2005
Oxford BioMedica plc ('the Company'or 'Oxford BioMedica')
Directors' Shareholdings
The Company today announces that on the 15 December 2005 it granted share
options over ordinary shares of 1 pence each in the Company ('share options') to
certain directors, under the Oxford BioMedica 1996 (No.1) share option scheme
('the Scheme'). The exercise price for each of the options is 29 pence per share
and no payment was made in respect of the grant of these share options.
Under the Scheme, the new share options may be exercised between 15 December
2008 and 15 December 2012. However, if at the time of exercise, or for at least
12 months in the three years before exercise, the percentage increase in Oxford
BioMedica's total shareholder return exceeds the percentage increase in the FTSE
TechMark Mediscience index since the date of the grant of the share option.
New share options to be granted
Professor Alan Kingsman 208,000
Professor Susan Kingsman 170,000
Peter Nolan 153,000
Andrew Wood 193,000
Nick Woolf 153,000
Following the grant of these share options, the interests of these directors in
options over ordinary shares of 1 pence each in the Company are:
New share options to be granted
Professor Alan Kingsman 578,000
Professor Susan Kingsman 475,000
Peter Nolan 883,028
Andrew Wood 1,258,891
Nick Woolf 1,086,124
Andrew Wood
Company Secretary, Oxford BioMedica plc
Tel. 01865 783000
16 December 2005
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.